Strategies for optimizing combinations of molecularly targeted anticancer agents

被引：283

作者：

Dancey, Janet E. ^{[1
]}

Chen, Helen X. ^{[1
]}

机构：

[1] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Rockville, MD 20852 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 08期

关键词：

D O I：

10.1038/nrd2089

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The rapid emergence of hundreds of new agents that modulate an ever-growing list of cancer-specific molecular targets offers tremendous hope for cancer patients. However, evaluating targeted agents individually, in combination with standard treatments, and in combination with other targeted agents presents significant development challenges. Because the number of possible drug combinations is essentially limitless, a strategy for determining the most promising combinations and prioritizing their evaluation is crucial. Here, we consider the crucial elements of a development strategy for targeted-agent combinations. Issues that pose challenges to the rational preclinical and clinical evaluation of such combinations will be described, and possible approaches to overcoming these challenges will be discussed.

引用

页码：649 / 659

页数：11

共 63 条

[11] Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J].

Ciardiello, F ;

Bianco, R ;

Caputo, R ;

Damiano, V ;

Troiani, T ;

Melisi, D ;

De Vita, F ;

De Placido, S ;

Bianco, AR ;

Tortora, G .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :784-793

[12]

De Soto JA, 2002, ANTICANCER RES, V22, P1007

[13] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[14] GENETIC INSTABILITY OF CELL-LINES DERIVED FROM A SINGLE HUMAN SMALL CELL-CARCINOMA OF THE LUNG [J].

ENGELHOLM, SA ;

VINDELOV, LL ;

SPANGTHOMSEN, M ;

BRUNNER, N ;

TOMMERUP, N ;

NIELSEN, MH ;

HANSEN, HH .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (07) :815-824

[15] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[16]

FERGUSON PJ, 1989, CANCER RES, V49, P1148

[17] Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma [J].

Friedman, HS ;

Kokkinakis, DM ;

Pluda, J ;

Friedman, AH ;

Cokgor, I ;

Haglund, MM ;

Ashley, DM ;

Rich, J ;

Dolan, ME ;

Pegg, AE ;

Moschel, RC ;

McLendon, RE ;

Kerby, T ;

Herndon, JE ;

Bigner, DD ;

Schold, SC .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3570-3575

[18] ENHANCEMENT OF NITROSOUREA ACTIVITY IN MEDULLOBLASTOMA AND GLIOBLASTOMA-MULTIFORME [J].

FRIEDMAN, HS ;

DOLAN, ME ;

MOSCHEL, RC ;

PEGG, AE ;

FELKER, GM ;

RICH, J ;

BIGNER, DD ;

SCHOLD, SC .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (24) :1926-1931

[19] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[20]

Gitler Miriam S., 2003, Molecular Cancer Therapeutics, V2, P929

← 1 2 3 4 5 6 7 →